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ABSTRACT 
Cystic fibrosis liver disease (CFLD) in children causes progressive fibrosis leading to biliary 
cirrhosis, however its cause(s) and early pathogenesis are unclear. We hypothesised that a 
bile acid-induced Ductular Reaction (DR) drives fibrogenesis. We evaluated the DR by 
cytokeratin-7 immunohistochemistry in liver biopsies, staged for fibrosis, from 60 children 
with CFLD and demonstrated that the DR was significantly correlated with hepatic fibrosis 
stage and biliary taurocholate levels. To examine the mechanisms involved in DR induction 
liver progenitor cells (LPCs) were treated with taurocholate and key events in DR evolution 
were assessed: LPC proliferation, LPC biliary differentiation and hepatic stellate cell (HSC) 
chemotaxis. Taurocholate induced a time-dependent increase in LPC proliferation and 
expression of genes associated with cholangiocyte differentiation (cytokeratin-19, connexin-
43, integrin-β4 and γ-glutamyltranspeptidase [GGT]), while the hepatocyte specification 
marker HNF4α was suppressed. Functional cholangiocyte differentiation was demonstrated 
via increased acetylated α-tubulin and SOX9 proteins, the number of primary cilia+ LPCs and 
increased active GGT enzyme secretion. Taurocholate induced LPCs to release MCP-1, 
MIP1α and RANTES into conditioned medium causing HSC chemotaxis, which was 
inhibited by anti-MIP1α. Immunofluorescence confirmed chemokine expression localized to 
CK7+ DR and LPCs in CFLD liver biopsies. This study suggests that taurocholate is involved 
in initiating functional LPC biliary differentiation and the development of the DR, with 
subsequent induction of chemokines that drive HSC recruitment in CFLD. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
INTRODUCTION 
 
Cystic fibrosis-associated liver disease (CFLD) is characterized by indolent intrahepatic 
cholestasis that usually manifests by early adolescence 1. Cystic fibrosis (CF) is caused by a 
defect in the gene coding for the cystic fibrosis transmembrane conductance regulator 
(CFTR) which, among other functions, maintains the flow of bile in contact with 
cholangiocytes by facilitating the movement of water and bicarbonate ions into bile. 
Abnormal ion/water transport leads to inspissated bile and cholestasis with focal fibrosing 
destruction of intrahepatic bile ducts 2. The resulting pattern of injury is focal biliary cirrhosis 
for which there is no known treatment and which may progress to cause portal hypertension, 
multilobular biliary cirrhosis and liver failure. However, only 10% of children with CF will 
develop portal hypertension and cirrhosis, a higher prevalence than the overall CF population, 
indicating a strong survival disadvantage. The cause and mechanism of this variable 
presentation and severity of pathology are not known 3. 
 
The Ductular Reaction (DR) is characterized by the expansion of a population of bipotential 
liver progenitor cells (LPCs) which can differentiate towards the cholangiocyte lineage into 
reactive bile ductules, as well as intermediate hepatocytes 4, 5. LPCs have been proposed by 
some groups to reside within peri-portal areas associated with the Canals of Hering 6, 
although their precise cellular origin is the subject of ongoing controversy 7. LPC expansion 
is thought to mediate a secondary pathway of liver regeneration, which occurs when the 
process of hepatocyte replication is overwhelmed in chronic liver disease 8. In cholestasis this 
expansion is postulated to be a futile attempt to drain excess bile via the formation of 
additional bile ductules and to replace damaged hepatocytes 9. The DR is observed along with 
activation of hepatic stellate cells (HSCs) and an increase in hepatic fibrosis, which is seen in 
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adult liver diseases that show periportal damage in cholestatic liver diseases 5, 10, as well as 
other conditions such as viral hepatitis A 11 and C 12, HFE-associated hemochromatosis 13, 
alcoholic and non-alcoholic fatty liver diseases 14 and post-transplant HCV 15. This has led to 
the hypothesis that the two processes of LPC expansion and HSC activation with the resultant 
DR and fibrosis, respectively, are closely related. While histological evidence of a DR has 
previously been demonstrated in children with extrahepatic biliary atresia 16, 17, the potential 
role of LPCs driving HSC activation and fibrosis via development of the DR has not 
previously been assessed in CFLD. 
 
Bile acids are synthesized in hepatocytes from cholesterol and are usually conjugated to 
taurine or glycine to form bile salts and secreted into the bile canaliculi. These bile secretions 
flow into bile ducts, where they are stabilized by bicarbonate ions and water secreted by 
cholangiocytes as they are excreted from the liver into the gall bladder. They aid lipid 
digestion in the duodenum by forming micelles. However, their partial hydrophobic nature, 
which is essential in forming micelles, also makes them toxic to the liver in higher 
concentrations 18. The bile salt composition within bile is altered in children with CFLD, as 
we have previously shown 19, and is comparable to that of mice following bile duct ligation 
20
. In particular, the hydrophobic bile salt, taurocholate is significantly increased in both bile 
and serum of children with CFLD 21. Taurocholate and other bile salts are able to upregulate 
the expression of inflammatory genes in the liver 22. Taurocholate has also been shown to 
stimulate cytokine secretion from cholangiocytes 23 and hepatocytes 21, which induce 
transdifferentiation of portal fibroblasts 24 as well as facilitating HSC migration 21, 25. We 
previously demonstrated that taurocholate induced the expression of monocyte chemotaxis 
protein-1 (MCP-1) in normal hepatocytes, and that MCP-1 produced by cholestatic 
hepatocytes from bile duct-ligated rats induced the chemotaxis of HSCs 21. Markedly 
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increased expression of MCP-1 was observed in hepatocytes and cholangiocytes in the liver 
of children with cholestatic liver diseases 21.  
 
In this study we investigated whether the DR is present in the liver of children with CFLD 
and examined mechanisms associated with its induction and role in fibrogenesis. We 
compared the severity of the DR in CFLD liver biopsies with those from other, more 
aggressively cholestatic pediatric liver disease and then specifically examined a potential 
mechanism of DR induction in CFLD through investigating the relationship between biliary 
taurocholate concentrations and the DR in liver biopsies from children with CFLD in vivo. 
We then used in vitro cell culture models and ex vivo liver slices to investigate the in vivo 
observed effects of elevated taurocholate on LPC differentiation, the secretion of chemokines 
by LPCs and their chemotactic effects on HSCs in driving hepatic fibrogenesis. 
 
MATERIALS AND METHODS 
 
Patient specimens. This study is part of a long-term prospective cohort study of patients with 
CFLD identified and referred from the CF Clinic, Royal Children’s Hospital, Brisbane, 
previously well documented 19, 21, 26-28. CFLD was defined as two of the following: (i) 
hepatomegaly ± splenomegaly; (ii) persistent (>6mo) elevation of serum alanine 
aminotransferase (>1.5x upper limit normal); and (iii) abnormal liver ultrasound (abnormal 
echogenicity or nodular edge). Those with liver synthetic dysfunction or a history of 
hepatobiliary surgery were excluded. The study conformed to the ethical guidelines of the 
1975 Declaration of Helsinki and was approved by the Ethics Committees of the Royal 
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Children’s Hospital, Brisbane and the QIMR Berghofer Medical Research Institute. Informed 
consent was obtained from parents or patients. 
 Liver tissue was available from 60 children with CFLD (age, 11.8±4.5yrs). For 
comparison with other pediatric cholestatic liver diseases, liver tissue was also available from 
three infants with biliary atresia (BA: age, 1.2±1.4yrs), five with idiopathic neonatal hepatitis 
(NH: age, 3.4±3.6yrs), as well as four pediatric donor liver controls (age, 6.8±4.5yrs). Bile 
was available from 7 children with CFLD. 
 
Immunohistochemistry. Formalin-fixed, paraffin-embedded liver sections were subjected to 
heat antigen retrieval, before exposure to 3% hydrogen peroxide in PBS and Background 
Sniper (Biocare Medical). Sections were then stained with primary antibody: mouse anti-
human CK7 mAb (1:100; DAKO), secondary antibody: rabbit anti-mouse biotinylated IgG 
(1:400, DAKO), with detection using a streptavidin-biotin/horseradish peroxidase kit 
(DAKO) and chromogenic substrate 3,3'-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich), and counterstained with hematoxylin. Digital images were captured using Aperio 
ScanScope XT slide scanner (Aperio Technologies) under 20x magnification at 0.5µm/pixel. 
Image analysis was performed using Aperio Positive Pixel Count algorithm v9.1. Positively 
stained cells were counted, normalized to the total section area and results correlated with 
Scheuer’s hepatic fibrosis staging. 
 
Biliary taurocholate measurement. Taurocholate concentration was measured in 
endoscopic bile samples available from seven patients with CFLD, as previously described 21. 
Liver biopsies were processed for histochemical CK7 quantification as above. All patients 
had histological evidence of hepatic fibrosis. Biliary taurocholate levels were correlated with 
CK7 quantification. 
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Culture of cell lines and in vitro studies. The murine LPC line PIL-2 29 was cultured in 
Williams’ E medium containing 2mM glutamine, penicillin (100 U/ml), streptomycin (100 
µg/ml), insulin (10 µg/ml), epidermal growth factor (10 ng/ml), insulin-like growth factor II 
(30 ng/ml) and 10% fetal bovine serum (FBS). The human HSC line LX-2 was cultured in 
DMEM with 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 2% FBS. 
PIL-2 cells were treated with taurocholate at 0-300µM concentration to establish a dose-
response, with an optimal concentration of 150µM taurocholate chosen for all in vitro and ex 
vivo experiments, as previously described 21. For differentiation assays, cells were lyzed 1-4 
days after taurocholate treatment. LPC differentiation was assessed using RT-qPCR and/or 
western blot analysis evaluating markers for cholangiocyte (connexin 43, Cx43; cytokeratin 
19, Ck19; integrin beta 4, Itgb4; γ-glutamyl transpeptidase, Ggt; epithelial cell adhesion 
molecule, EpCam; SYR-related HMG box transcription factor 9, Sox9) and hepatocyte 
(albumin; hepatocyte nuclear factor 4α, Hnf4α) phenotype.  
 
RT-qPCR for LPC differentiation marker and chemokine mRNA expression. RNA was 
extracted from both untreated and taurocholate-treated PIL-2 cells using the RNeasy kit 
(Qiagen) and 1µg was reverse-transcribed into cDNA using SensiFast (Bioline). Real-time 
qPCR was performed on a Biorad CFX96 with HPRT used as the reference gene. Primers are 
listed in Table 1. 
 
MTT cell proliferation assay. Cell proliferation was measured over a two hour period at 1-4 
days following treatment of PIL-2 cells with 150µM sodium taurocholate using the method of 
Alley et al. 30. Absorbance was measured at 570nm with a 620nm reference filter. 
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Western blot analysis.  
Cell lysates were prepared from PIL-2 cells disrupted in RIPA buffer with Complete EDTA-
free protease inhibitors (Roche). Lysates were resolved on 10% SDS-PAGE gels as described 
in Laemmli et al. 31 and transferred to polyvinyl difluoride membranes (Immobilon-FL; 
Millipore). Membranes were probed with anti-CK19 (Abcam ab15463; 1:2000); anti-SOX9 
(Merck Millipore #AB5535; 1:1000); anti-HNF4α (Santa Cruz sc6556; 1:1000); anti-
acetylated α-tubulin (Sigma-Aldrich T7451; 1:1000); with anti-β-actin used to detect the β-
actin loading control (Cell Signaling; 1:2000), in TBST LI-COR Odyssey blocking buffer. 
Blots were probed with an anti-mouse 680RD or anti-rabbit 800CW secondary at 1:20000 in 
TBST LI-COR Odyssey blocking buffer. Secondary localization was detected with the LI-
COR Odyssey CLx Infrared Imaging System. Band quantification was performed using 
Image Studio Lite version 5.2.  
 
Immunofluorescence. To examine primary cilia, PIL-2 cells were grown on glass coverslips 
to 60-80% confluence and treated for three days ± 150µM taurocholate and serum-starved 
overnight prior to fixation. Cells were placed at 4°C for 30 minutes to destabilize 
microtubules and then fixed in 4% paraformaldehyde for 10 minutes. Cells were 
permeabilized with 0.5% Triton X-100, blocked with 5% BSA and probed with mouse anti-
acetylated α-tubulin (Sigma-Aldrich; 1:600) and rabbit anti-γ-tubulin (Sigma-Aldrich; 1:400) 
antibodies overnight in PBST with 1% BSA. Primary binding was probed with AlexaFluor 
594 donkey anti-rabbit (Invitrogen) and AlexaFluor 594 goat anti-mouse (Invitrogen) at 
1:500 for 1hr in PBST with 1% BSA. Images were captured with a Zeiss AxioScop2. 
Quantification of acetylated α-tubulin spots was performed using Particle Analysis in ImageJ 
(NIH). 
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To identify the cellular source of HSC chemokines in liver biopsies from children with 
CFLD, we performed dual immunofluorescence for chemokines MCP-1; regulated upon 
activation, normal T cell expressed and secreted (RANTES); or macrophage inflammatory 
protein 1α (MIP1α), together with the LPC/DR marker, CK7. Primary antibodies used were: 
mouse anti-CK7 mAb (1:150, Abcam), goat anti-human MCP-1 pAb (1:8, R&D Systems), 
goat anti-human CCL5/RANTES pAb (1:83, R&D Systems), goat anti-human MIP1α (1:50, 
R&D Systems), incubated overnight at 4oC followed by a 30 min incubation step at room 
temperature with donkey anti-mouse IgG AlexaFluor 555 (1:300, Invitrogen) and donkey 
anti-goat IgG AlexaFluor 488 (1:300, Molecular Probes). Sections were mounted in Prolong 
Gold (Invitrogen) with DAPI and examined by confocal microscopy (Zeiss 780NLO). 
 
Ex vivo liver slice studies. Precision-cut liver slices were performed as previously described 
32
. A minimum of three liver slices each from three separate C57BL6 WT mice for each time 
point and each treatment group, were incubated in Williams’ E medium containing 2mM 
glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FBS at 37°C for two 
and four days ± 150µM taurocholate. Conditioned medium was examined for GGT enzyme 
activity. Slices were harvested for mRNA quantitation using RT-qPCR. 
 
γ-Glutamyl Transpeptidase Activity Assay. GGT activity was determined from in vitro cell 
cultures and ex vivo liver slice conditioned media using the GGT activity colorimetric assay 
kit (Sigma-Aldrich). Protein for normalization was measured using the Pierce BCA protein 
assay (Thermo Fisher Scientific). 
 
Quantification of cytokine protein secretion from LPCs ± taurocholate. Chemokines 
MCP-1, MIP1α and RANTES, released from LPCs, were quantified using the Cytokine Bead 
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Array (CBD; BD Biosciences), according per manufacturer’s protocol. The concentrations of 
transforming growth factor-1β (TGF-β1) and platelet-derived growth factor–BB (PDGFB) 
secreted by LPCs were determined by ELISA (R&D Systems). 
 
Chemotaxis assays. Induction of HSC chemotaxis via taurocholate treatment of LPCs was 
examined by measuring cell migration through 8µm 24-well cell culture inserts (Greiner Bio-
One) in modified Boyden chambers. Assays were performed using 0.5x106 LX-2 cells (serum 
starved overnight) per ml within the insert and the inserts were placed suspended within test 
medium. Test medium was either normal non-conditioned serum-free Williams’ E medium or 
conditioned medium from LPCs ± taurocholate. Chemokine neutralization was performed by 
pre-treating conditioned medium with 2.5 µg/ml anti-mouse MCP-1 (AF-479-NA), 1 µg/ml 
anti-mouse MIP1α (AF-450-NA) or 1 µg/ml anti-mouse RANTES (AF478) polyclonal 
neutralization antibodies (R&D Systems), 1hr prior to the assay. Testing of MIP1α as 
chemokine used murine (R&D Systems; 40-337) or human (R&D Systems; 40-364) 
recombinant purified MIP1α proteins. Blocking of the CCR5 receptor used the 
neutralization/blocking antibody MAB182 (R&D Systems) applied to the LX-2 cells within 
the Boyden chamber insert for 1 h prior to the assay at an insert concentration of 20 µg/ml. 
Chemotaxis assay were performed for 24h and migrated cells on the underside of the insert 
membrane were stained with Cell Stain (Part No. 90144; Merck-Millipore), treated with 
Extraction Buffer (Part No. 90145; Merck-Millipore) and absorbance measured at 560nm. 
Results from separate experimental replicates were normalized to the mean absorbance of 
control samples (non-conditioned serum-free assay medium and FBS positive control). 
 
Statistical analysis. Results are presented as mean ± SEM. Statistical analysis was performed 
with GraphPad Prism 6 (GraphPad Software Inc.). For immunohistochemical analysis: Mann-
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Whitney test and one-way non-parametric ANOVA analysis with Kruskal-Wallis and Dunn’s 
multiple comparison test. For chemotaxis assay: One-way ANOVA with Sidak’s multiple 
comparison. For qPCR time course: ANOVA with Sidak’s post-hoc test and two-way 
ANOVA to examine the overall treatment effect. For qPCR chemokine expression: unpaired 
t-test. For CBA assay: unpaired t-test with Welch’s correction. Differences were considered 
significant when p<0.05. 
 
RESULTS 
 
Ductular Reaction correlates with fibrosis and biliary taurocholate in CFLD. The DR, as 
assessed by CK7 expression, was markedly increased in CFLD and contained expanded 
reactive bile ducts, and both single LPCs and strings of biliary cells/LPCs (Figure 1). The 
DR was mainly present in the periphery of portal tracts as irregular strands/chords of CK7+ 
cells and as isolated single CK7+ LPCs in adjacent areas. This DR was increased in CFLD 
(p<0.05), as well as in BA (p=0.114) and NH (p=0.016) versus controls (Figure 2A). When 
stratified for fibrosis stage, there was a highly significant positive correlation between CK7 
staining and increasing fibrosis stage in CFLD (Spearman r = 0.59, p < 0.0001) (Figure 2B). 
Bile samples were available from 7 of the 60 children with CFLD. There was a positive 
statistical correlation between biliary taurocholate concentrations and the extent of the DR as 
assessed via CK7 quantification (r = 0.528; p = 0.0321) (Figure 2C). 
 
Taurocholate induces biliary differentiation of LPCs. As we demonstrated that in CFLD 
the extent of the DR correlates with both fibrosis severity and biliary taurocholate levels, we 
hypothesized that taurocholate may induce LPC biliary differentiation and the DR. To 
interrogate this hypothesis, we treated the murine LPC line PIL-2 with 0-300 µM 
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taurocholate for four days to establish the optimal conditions for all in vitro and ex vivo 
studies. Taurocholate induced a dose-dependent increase in mRNA expression of the 
cholangiocyte markers Cx43 (Figure 3A; ANOVA, p<0.0001) and Ck19 (Figure 3B; 
ANOVA, p<0.0001). A taurocholate concentration of 150µM was chosen for all subsequent 
experiments as has previously been described in in vitro studies 21, 23, and also being 
consistent with previous observations in children with CFLD that displayed a mean biliary 
taurocholate concentration of 108µM vs 41µM in healthy controls 21. 
 
PIL-2 cells were treated with 150µM taurocholate for 0-4 days and markers of cholangiocyte 
differentiation were further assessed. Taurocholate induced a time-dependent increase in 
mRNA expression of cholangiocyte markers Cx43 (Figure 3C; ANOVA p<0.0001), Ck19 
(Figure 3D; ANOVA p<0.0001), Itgb4 (Figure 3E; ANOVA p<0.029), and Ggt (Figure 3F; 
ANOVA p<0.001). Taurocholate treatment did not significantly alter expression of two other 
cholangiocyte markers, EpCam and Sox9 (data not shown). 
 
Of interest, we observed a concomitant decrease in mRNA expression of the master regulator 
of hepatic differentiation, Hnf4α (Figure 4A; ANOVA p=0.0255). A second hepatocyte 
marker, albumin (Alb) showed no significant difference with taurocholate treatment (Figure 
4B). Taken together, these results suggest that taurocholate augments the cholangiocytic 
differentiation of the LPC line PIL-2. 
 
LPC proliferation is induced by taurocholate. Integral to the formation of the DR is the 
expansion of LPCs in chronic liver disease. To assess the potential effect of taurocholate on 
LPC proliferation, PIL-2 cells ± 150µM taurocholate were subjected to an MTT cell 
proliferation assay every 24 hrs for 1-4 days. Taurocholate induced a time-dependent increase 
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in LPC proliferation (Figure 5; ANOVA, p=0.0003), which was most notable early, i.e., after 
1-2 days.  
 
Taurocholate induces differentiation of LPCs into functional cholangiocytes While 
Figure 3 demonstrates that taurocholate induced the expression of cholangiocyte-associated 
genes in LPCs, an assessment of actual cholangiocyte function remained to be confirmed. 
Thus, we examined expression of proteins involved in various aspects of biliary cell function. 
We observed that CK19, a protein responsible for the structural integrity of cholangiocytes is 
significantly induced by taurocholate (Figure 6A and B; p=0.0006). Taurocholate also 
induced a significant >2.5-fold increase in SOX9 protein, a key transcriptional regulator of 
cholangiocyte differentiation and bile duct formation (Figures 6A and C; p=0.001). 
Conversely, HNF4α protein expression, a marker and transcriptional regulator of hepatocyte 
specification, was significantly decreased by taurocholate (Figures 6A and D; p=0.019). 
 
One key morphological characteristic of cholangiocytes is the presence of primary cilia with 
acetylated α-tubulin being a key structural component. Western blot analysis revealed a 
significant induction of acetylated α-tubulin protein expression in taurocholate-treated LPCs 
(Figures 6A and E; p=0.026). As acetylated α-tubulin can also be found within other cellular 
structures such as microtubule networks, we further investigated the cellular localization of 
acetylated α-tubulin using immunofluorescence of LPCs ± taurocholate. Expression of 
acetylated α-tubulin causes primary cilia to appear as discrete dots or lines, while 
microtubule networks form thin filament-meshed patterns 33. As can be seen in Figure 7A, 
taurocholate induced a marked increase in the number of acetylated α-tubulin+ primary cilia 
when compared to controls, with quantitation of the relative fluorescence showing a 2.4-fold 
increase (p=0.022) (Figure 7B). 
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Another measure of functional LPC-cholangiocyte differentiation is the production of 
enzymatically active GGT, which is expressed and released by cholangiocytes within bile 
ducts. PIL-2 cells were treated ± 150µM taurocholate for 1-4 days with conditioned medium 
removed for analysis every 24hrs. Taurocholate induced a significant time-dependent 
increase in GGT activity (ANOVA, p<0.0001), with maximal production between days 3-4 
(Figure 7C). At the conclusion of the experiment (day 4), this result remained highly 
significant when corrected for cellular protein concentration (Supplementary Figure S1). 
 
The effect of taurocholate in ex vivo precision-cut liver slices. To demonstrate potential 
physiological relevance of our in vitro observation, we used precision-cut liver slices from 
normal control mice, treated ± 150µM taurocholate for up to four days. The hepatic mRNA 
expression of Cx43, as a representative cholangiocyte marker, was significantly increased in a 
time-dependent manner (Figure 8A; ANOVA, p=0.0354). Conditioned medium collected 
was assayed for GGT activity and normalized to liver slice wet weight. Taurocholate again 
induced a significant increase in GGT activity, peaking at day 2 (Figure 8B; ANOVA, 
p=0.0021). 
 
Chemokine expression induced by taurocholate in LPCs. PIL-2 cells treated with 150µM 
taurocholate showed significantly increased expression of MCP-1, MIP1α, and RANTES 
mRNA at 6hrs (Figure 9A). We also examined the gene expression of the profibrotic 
cytokine TGF-β1 and HSC mitogen PDGFB, which both have HSC chemotactic potential. 
While taurocholate induced increased expression of both TGF-β1 and PDGFB, this did not 
reach statistical significance (Figure 9A). 
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Conditioned medium from PIL-2 cells ± 150µM taurocholate for 6hrs or 24hrs was assessed 
for protein secretion of key hepatic chemokines. Rantes, Mcp-1, Mip1α, Tgf-β1 and Pdgfb 
were all expressed constitutively by PIL-2 cells. After 6hrs taurocholate treatment resulted in 
a 2-fold increase in MIP1α protein release (p<0.0001), whereas RANTES and PDGFB 
increased by approximately 1.5-fold (Figure 9B). Taurocholate induced an increase in MCP-
1 secretion, however this did not reach statistical significance. By 24hrs, chemokine levels 
were indistinguishable from controls, except for PDGFB, which remained elevated in 
response to taurocholate (p<0.05). No effect was observed on TGF-β1 release. 
 
HSCs migrate in response to chemokines secreted by taurocholate-treated LPCs. 
Chemotaxis of the LX-2 HSC line was significantly induced by conditioned medium from 
PIL-2 cells treated with taurocholate for either 6hrs (p<0.001) or 24hrs (p<0.01) (Figure 
10A). Similar levels of chemotaxis were demonstrated using primary rat HSCs (data not 
shown). To determine the identity of chemokines responsible for this chemotaxis, 
conditioned medium was pre-treated with neutralizing antibodies to various different 
chemokines. Chemotaxis was completely inhibited by anti-MIP1α neutralizing antibody 
(nAb), however, anti-RANTES nAb had no effect (Figure 10B). While chemotaxis of LX-2 
cells was partially suppressed using anti-MCP-1 nAb, this did not reach statistical 
significance. 
 
HSCs migrate in response to MIP1α mediated by CCR5. As shown in Fig 10B, 
chemotaxis of HSCs in response to conditioned medium from PIL-2 cells treated with 
taurocholate was inhibited by anti-MIP1α nAb. To strengthen the case for the involvement of 
MIP1α as a HSC chemotactic agent, a chemotaxis assay was performed on LX2 cells using 
either murine or human recombinant purified MIP1α. Both murine (Figure 11A; ANOVA, 
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p=0.022) and human (Figure 11B; ANOVA, p=0.0009) MIP1α produced a significant dose-
dependent increase in HSC migration approaching the effect observed with the positive 
control (FBS). 
 LX-2 cells were examined for the expression of both known major hepatic MIP1α 
receptors, C-C chemokine receptor type 1 and 5 (CCR1 and CCR5). Using quantitative RT-
PCR, expression of both Ccr1 and Ccr5 was demonstrated, with Ccr5 showing higher mRNA 
levels vs. Ccr1 (Supplementary Figure S2). To investigate if CCR5 was the major 
contributing receptor in HSC chemotaxis, LX-2 cells were pre-treated with an anti-CCR5 
nAb. This antibody effectively attenuated the migration of LX-2 HSCs in response to both 
recombinant murine MIP1α (Figure 11C) and conditioned medium from PIL-2 cells treated 
with 150µM taurocholate (Figure 11D). 
 
DR cells and LPCs express chemokines in liver from children with CFLD. To assess the 
potential clinical relevance of taurocholate-induced chemokine expression demonstrated in in 
vitro and ex vivo studies, liver sections from patients with CFLD (n=22) were examined for 
the cellular source of chemokines. Dual immunofluorescence confirmed that CK7+ DR cells, 
and single CK7+ LPCs, express MCP-1 (Figure 12A), RANTES (Figure 12B) and MIP1α 
(Figure 13A and B). 
 
DISCUSSION 
 
The DR is proposed to be associated with the initiation of hepatic fibrosis in a number of 
chronic liver diseases 4, 12, 34, 35. However, the precise mechanisms involved in its induction 
and indeed in the interactions between LPCs and HSCs, which may drive both the DR and 
fibrogenesis, remain to be elucidated. This histological process has been reported in many 
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adult liver diseases including chronic hepatitis C 12, alcoholic and non-alcoholic 
steatohepatitis 14, 35 and genetic hemochromatosis 13. In these diseases, the DR correlates 
closely with severity of fibrosis and inflammation 34. However, the presence or role of the DR 
has not previously been investigated in children with CFLD. Here we show that the DR is 
indeed present in CFLD (and comparable to the DR present in more aggressive pediatric 
fibrosing cholestatic diseases such as biliary atresia 36, 37) and the extent of the DR 
significantly correlates with fibrosis staging in CFLD, suggesting that mechanisms regulating 
these two processes are interrelated. 
 
Extensive investigation into the individual mechanisms of LPC and HSC activation 38 have 
elucidated a role for many different soluble mediators in hepatic fibrosis. Understanding the 
interaction between LPCs and HSCs is of great importance for clarifying the contribution of 
these cells in mediating fibrogenesis and for designing therapeutic strategies aimed at 
reduction of hepatic fibrosis. 
 
Bile salt retention is part of the proposed mechanism of injury and biliary fibrosis in CFLD 
and we previously demonstrated that biliary/serum levels of the conjugated bile acid 
taurocholate are elevated in children with CFLD 21. In the present study we demonstrated that 
the extent of the DR correlates with biliary taurocholate concentration in children with CFLD 
and thus speculate a potential mechanistic link. To determine whether taurocholate plays a 
role in inducing the DR, we used both an LPC in vitro cell culture model and ex vivo 
precision-cut liver slices, and employed a reductionist strategy to examine the impact of 
taurocholate on three key events in the evolution of the DR: LPC proliferation, biliary 
differentiation of LPCs and HSC chemotaxis.  
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In this study, we demonstrated that taurocholate increased LPC proliferation in vitro, 
suggesting that taurocholate may play a role in enhancing LPC expansion as part of the DR in 
CFLD. This observation is supported by studies from Clouzeau-Girard et al. 39 showing that 
taurocholate leads to uncharacterized cell proliferation around the portal tracts in ex vivo liver 
slices. Our data are also consistent with the observation that feeding taurocholate to rats 
increases cholangiocyte numbers 40, although this study did not distinguish whether these 
were mature adult cholangiocytes or derived from LPCs. 
 
The biliary differentiation of LPCs and subsequent formation of reactive bile ductular 
structures appear to be an important component of DR development. We demonstrated a 
significant increase in expression of the cholangiocyte genes Ck19, Cx43, Itgb4 and Ggt1 in 
response to taurocholate treatment of LPCs. Conversely, the hepatocyte lineage marker 
Hnf4α was decreased, with albumin expression unchanged. This in vitro result may be 
consistent with LPC differentiation that occurs during the DR in vivo and provides one 
potential mechanism for induction of the DR in pediatric cholestatic liver diseases such as 
CFLD. Further supporting this concept, we demonstrated that taurocholate induced functional 
cholangiocyte differentiation, evidenced through the increased expression of acetylated α-
tubulin, CK19 and SOX9 protein, increased numbers of LPCs elaborating primary cilia, as 
well as the secretion of enzymatically active GGT in vitro. The effect of taurocholate on 
cholangiocyte function was further confirmed in ex vivo precision-cut liver slices, showing 
induced expression of Cx43 mRNA and secretion of active GGT.  
 
In addition, this study has demonstrated that taurocholate-exposed LPCs secrete a number of 
chemokines including MCP-1, MIP1α, RANTES and PDGFB, however HSC chemotaxis in 
response to taurocholate-treated LPC conditioned medium appears principally due to MIP1α. 
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Neutralizing antibodies to either MIP1α in LPC conditioned medium or the MIP1α receptor 
CCR5 on HSCs attenuated TCA-treated LPC-induced HSC chemotaxis. Thus, we propose 
that MIP1α derived from bile acid-exposed LPCs, may recruit HSCs (via CCR5) during the 
DR and aid in the initiation of hepatic fibrosis in CFLD. We did not demonstrate that 
RANTES aided in the chemoattraction of HSCs. Neutralization of MCP-1 resulted in a 
limited inhibition of HSC chemotaxis, however this did not reach statistical significance due 
to biological variability of the data. RANTES and MCP-1 may induce recruitment of other 
cells to the LPC niche as part of the fibrogenic process such as additional LPCs or 
inflammatory cells, as we previously described 21, 41. Migration of HSC towards LPCs as well 
as HSC activation could explain why fibrosis begins in periportal regions of the liver, where 
there is decreased bile flow through bile ducts, and thus increased accumulation of 
hydrophobic bile acids 19. This pattern of chemokine expression upon in vitro taurocholate 
treatment may be indicative of the specific role of LPCs in generating a microenvironment 
that aids in the activation of HSC. In the current study, immunofluorescence revealed that 
MCP-1, RANTES and MIP1α are all expressed by DR cells and CK7+ LPCs in liver from 
children with CFLD, providing in vivo evidence validating our in vitro observations. 
 
HSC activation is also influenced by other cell types present during chronic liver injury and 
inflammation, as the LPC niche harbours immune cells including liver macrophages, which 
also secrete MCP-1, MMPs, TIMPS 42, 43 and chemokines. The downstream chemoattractive 
effect caused by exposure of LPCs to increased levels of taurocholate appears likely to recruit 
HSCs into the LPC niche and places these two cell types within close proximity and 
potentially in direct contact. Supporting this, activated HSCs have been observed adjacent to 
LPCs in various mouse model of fibrosis 33, 41, 44 as well as in human liver diseases 13, 45, 
demonstrating recruitment of each cell type towards the other during fibrosis. Various studies 
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have also suggested that membrane contact (and cross-talk) between LPCs and HSCs is a key 
mediator of fibrogenesis 41, 46, 47. In this context, our previous work showed that HSCs treated 
with the TNF superfamily member, lymphotoxin-β, induces NFκB signalling, upregulating 
chemotaxis-associated factors such as RANTES and ICAM-1, aiding in LPC and 
inflammatory cell recruitment. As HSCs express the lymphotoxin-β receptor on their cell 
surface and lymphotoxin-β is a membrane-bound ligand on LPCs, this suggests that direct 
cell-cell contact between LPCs and HSCs may be required to initiate chemokine expression 
41
. Adding to the complexity of this system, high concentrations of taurocholate have also 
been shown to induce inflammatory gene expression in hepatocytes as well as 
cytokine/chemokine secretion that may also lead to HSC recruitment and activation 21, 22. The 
present study suggests that the DR precedes fibrosis. However, there is an alternate 
hypothesis stating that fibrosis precedes the DR and there is some evidence to support this in 
animal studies 48. It is also possible that the two processes may be injury context-specific thus 
further investigations are warranted to fully elucidate the temporal nature of LPC niche 
development. In addition to HSCs, portal fibroblasts may also contribute to CFLD. However, 
while previous studies have shown that both activated HSCs and myofibroblasts produce 
collagen in this disease 26, the role of myofibroblasts derived from portal fibroblasts and 
indeed the potential recruitment by, and interaction between, these cells and LPCs has not 
been previously investigated. 
 
In conclusion, this study has shown that the DR is present in CFLD and is correlated with 
biliary taurocholate levels as well as increasing hepatic fibrosis severity. Thus, we propose 
that the following model may in part help to explain the pathogenesis of CFLD (Figure 14). 
In this model, the CFTR defect causes thickened mucous secretions and obstruction of the 
intrahepatic bile ducts. This obstruction elevates biliary levels of bile salts such as 
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taurocholate in the vicinity of LPCs, induced as a result of hepatic injury and potentially 
compromised hepatocyte replication associated with the chronic nature of liver injury in 
CFLD. In response to supraphysiological levels of bile salts, LPCs firstly undergo 
proliferation followed by differentiation towards cholangiocytes as part of the DR. Also, in 
response to altered bile salt levels, LPCs secrete chemokines including MCP-1, MIP1α and 
RANTES, and this likely attracts HSCs and other immune/inflammatory cells to the LPC 
niche. Cell-cell contact between LPCs and recruited HSCs may result in activation of HSCs 
and subsequent fibrogenesis, at least in part via interaction between the HSC lymphotoxin-β 
receptor via cognate ligands on LPCs, with further inflammatory niche chemotaxis, as we 
previously described 41. Increased understanding of the role of hydrophobic bile acids in 
CFLD and their impact on the LPC niche, cellular cross-talk with HSCs and induction of the 
DR will provide important new knowledge of clinical relevance, which may aid in the 
development of targeted therapeutic strategies to reduce fibrosis in CFLD and potentially in 
other pediatric cholestatic disorders. 
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FIGURE LEGENDS 
 
Figure 1. Evidence of the DR in CFLD. Immunohistochemistry for CK7 expression in the 
liver of (A) a donor control subject (10x magnification; 200µm scale bar) and (B, C) a child 
with CFLD. The CFLD patient shows (B) a marked DR (8x magnification; 160µm scale bar), 
and (C) numerous single CK7+ LPCs adjacent to areas of DR (40x magnification; 60µm scale 
bar).  
 
Figure 2. Assessment of the Ductular Reaction in CFLD and other pediatric cholestatic 
liver diseases. (A) CK7 expression in three pediatric cholestatic liver diseases: CFLD, cystic 
fibrosis liver disease; BA, biliary atresia; NH, idiopathic neonatal hepatitis vs. donor control 
livers. Statistical calculations were performed using an ANOVA with Kruskal-Wallis test 
where *p<0.05. (B) Correlation between CK7 expression and hepatic fibrosis stage in livers 
of children with CFLD (Spearman r=0.59, p<0.0001). Statistical calculations were performed 
using an ANOVA with Kruskal-Wallis test where *p<0.05, and **p<0.01. (C) Correlation 
between hepatic CK7 expression and biliary taurocholate levels in children with CFLD (n=7; 
Pearson r2=0.528; one-tailed p=0.0283). All data represent mean ± SEM. 
 
Figure 3. Taurocholate induces markers of cholangiocyte differentiation in LPCs. 
Taurocholate (0-300µM) induced a dose-dependent increase in mRNA expression of 
cholangiocyte markers (A) Cx43 (ANOVA, p<0.0001) and (B) Ck19 (ANOVA, p<0.0001) in 
PIL-2 cells (n=4). Dunnett's multiple comparisons test was performed relative to untreated 
cells. PIL-2 cells (n=4) treated with 150µM taurocholate for up to 4 days induced a time-
dependent increase in the mRNA expression of cholangiocyte markers (C) Cx43 (ANOVA, 
p<0.0001), (D) Ck19 (ANOVA, p<0.0001), (E) Itgb4 (ANOVA, p=0.029), and (F) Ggt1 
(ANOVA, p=0.001), expressed relative to vehicle control at each time point. Sidak's multiple 
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comparisons test was used for comparison at individual time points. All data represented as 
mean ± SEM and p values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001. 
 
Figure 4. The effect of taurocholate on markers of hepatocyte differentiation in LPCs. 
PIL-2 cells treated with 150µM taurocholate for up to 4 days resulted in a time-dependent 
decrease in mRNA expression for the hepatocyte marker (A) Hepatocyte nuclear factor 4α 
(Hnf4α; ANOVA, p=0.0255), expressed relative to vehicle control at each time point, 
although there was no apparent effect on (B) Albumin (Alb) expression (n=4). All data 
represented as mean ± SEM. 
 
Figure 5. LPC proliferation is induced by taurocholate. Taurocholate (150µM) induced a 
time-dependent increase in cell proliferation (ANOVA, p=0.0003) in PIL-2 cells treated for 
0-4 days, as assessed using an MTT assay (n=4). Sidak's multiple comparisons test was 
performed for treatment comparison at individual time points where **p<0.01. All data 
represent mean ± SEM. 
 
Figure 6. Taurocholate induces functional characteristics of biliary differentiation in 
LPCs in vitro at the protein level. PIL-2 cells were treated with 150µM taurocholate for 4 
days. (A) Western blot analysis (n=4) revealed an increased expression of CK19 and SOX9 
proteins, while HNF4α protein expression was decreased, relative to the β-actin loading 
control. Increased expression of acetylated α-tubulin protein relative β-actin was also 
observed. Band quantification from infrared imaging demonstrated that taurocholate induced 
statistically significant increases in (B) CK19, (C) SOX9 and (E) acetylated α-tubulin, while 
conversely, (D) HNF4α protein expression was significantly decreased. Data are expressed as 
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mean ± SEM and statistical significance was assessed using Student's t-test where *p<0.05 
and ***p<0.001.  
 
Figure 7. Taurocholate induces morphological and biochemical characteristics of 
functional biliary differentiation in LPCs in vitro. (A) PIL-2 cells (n=3) grown on 
coverslips were treated with 150µM taurocholate for three days vs untreated controls and 
serum starved overnight to enhance cilia production. Cells were examined (100x 
magnification) for the presence of primary cilia via expression of acetylated α-tubulin 
(green). Cells were also labelled with the nuclear strain (DAPI). These images show an 
increase in the number of primary cilia in response to taurocholate, which when individually-
stained spots/lines of fluorescence were quantified (B) show a statistically significant 2.4-fold 
increase using Student’s t-test (n=3) where **p<0.01. Data are expressed as mean ± SEM. 
(C) Taurocholate (150µM, 1-4 days) induced a time-dependent increase in GGT enzyme 
activity (represented as nmole of p-nitroanilide/hour/ml) in conditioned media from PIL-2 
cells (n=4; ANOVA, p<0.0001). Sidak's multiple comparisons test was performed for 
comparison at individual time points where **p<0.01 and ****p<0.0001. All data represent 
mean ± SEM. 
 
Figure 8. Effect of taurocholate in an ex vivo liver model. To demonstrate the potential 
physiological relevance of our in vitro observation, we used precision-cut liver slices (in 
triplicate from each of n=3 mice) treated with 150µM taurocholate for 4 days to demonstrate 
a time-dependent increase in (A) mRNA expression of the cholangiocyte marker Cx43 
(ANOVA, p=0.0354), as well as (B) GGT enzyme activity normalised to tissue weight (6 
replicates from each of n=3 mice; ANOVA, p=0.0021). All data represent mean ± SEM. 
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Figure 9. Profiling of hepatic chemokines expressed and secreted by LPCs after 
taurocholate treatment. (A) Taurocholate induced a significant increase in Mcp-1, Mip1α, 
and Rantes mRNA expression in PIL-2 cells at 6 hours. Statistical significance for each gene 
transcript was assessed using Student's t-test where *p<0.05 and ***p<0.001. (B) 
Taurocholate treatment induced a significant increase in MIP1α and RANTES protein release 
into the culture medium at 6 hours. MCP-1 and PDGFB were also increased but this did not 
reach statistical significance. The effect of taurocholate was lost after 24 hours, except for the 
effect on PDGFB (p=0.0153). TGF-β protein release was not affected by taurocholate 
treatment. All data represented as mean ± SEM and p values are indicated as follows: 
*p<0.05 and ***p<0.001. 
 
Figure 10. Treatment of LPCs with taurocholate induces HSC chemotaxis.  PIL-2 cells 
were treated with 150µM taurocholate for 6 hours or 24 hours and conditioned medium (CM) 
from these cells was used in modified Boyden chambers to examine LX-2 chemotaxis after 
24 hours. (A) Treatment of LX-2 HSCs with conditioned medium from either 6 or 24 hour 
taurocholate-treated PIL-2 cells resulted in significant HSC chemotaxis across the Boyden 
chamber membranes (n>4). (B) Chemotaxis of LX-2 cells induced by conditioned medium 
from 24 hour taurocholate-treated PIL-2 cells was inhibited by anti-MIP1α antibody. 
Statistical significance was determined using ANOVA with Sidak's multiple comparisons test 
performed for specific comparisons. All data represent mean ± SEM and p values are 
indicated as follows: **p<0.01, ***p<0.001, and ****p<0.0001. 
 
Figure 11. MIP1α induces HSC chemotaxis. LX-2 cells were placed in modified Boyden 
chambers with physiologically relevant concentrations of either (A) murine recombinant 
MIP1α or (B) human recombinant MIP1α and assessed for chemotactic potential. MIP1α 
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produced a significant dose-dependent increase in HSC chemotaxis (ANOVA, p=0.022 and 
p=0.0009, respectively; n=3). Sidak's multiple comparisons test was performed for treatment 
comparison where *p<0.05. (C) The chemoattractive effect of murine recombinant MIP1α 
was attenuated by pre-treating LX-2 cells with an anti-CCR5 neutralizing antibody (n=4). (D) 
Pre-treatment of LX-2 cells with anti-CCR5 also attenuated chemotaxis in response to 
conditioned medium from 24 h taurocholate-treated PIL-2 cells (n=4). ANOVA with Sidak's 
multiple comparisons test was performed for specific comparisons where **p<0.01 and 
****p<0.0001. All data are expressed as mean ± SEM. 
 
Figure 12. Cellular localization of MCP-1 and RANTES expression in liver from 
children with CFLD. Dual immunofluorescence was performed on CFLD patients to 
demonstrate the colocalization of CK7+ DR cells with (A) MCP-1 protein expression (63x 
magnification; 20µm scale bar) and (B) RANTES protein expression (40x magnification; 
50µm scale bar). Sections are shown with DAPI (4',6-diamidino-2-phenylindole) in blue, 
CK7 in red, and either MCP-1 or RANTES in green, with colocalization (merge). 
 
Figure 13. Cellular localization of MIP1α expression in liver from children with CFLD. 
Dual immunofluorescence was performed on CFLD patients for the association of MIP1α 
protein expression with (A) clusters of CK7+ DR cells (40x magnification; 1.4 zoom; 20µm 
scale bar) and (B) individual CK7+ LPCs (63x magnification; 20µm scale bar). Sections are 
shown with DAPI (4',6-diamidino-2-phenylindole) in blue, CK7 in red, and M1Pα in green 
with colocalization (merge). 
 
Figure 14. Proposed model for taurocholate-induced DR and fibrogenesis in children 
with CFLD. The cystic fibrosis transmembrane conductance regulator (CFTR) defect results 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
in obstruction of the intrahepatic bile ducts (red cross). This obstruction elevates biliary 
taurocholate levels, which drives LPC proliferation and biliary/cholangiocyte differentiation 
as part of the DR. In response to increased taurocholate, LPCs secrete chemokines that attract 
HSCs/myofibroblasts (and likely other immune/inflammatory cells) to the LPC niche and/or 
the region of DR development. Cell-cell contact between LPCs and recruited HSCs may 
result in activation of HSCs and subsequent fibrogenesis. 
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Table 1: List of qPCR Primers: https://www.ncbi.nlm.nih.gov/nuccore/ 
Primers NCBI accession Forward Reverse 
Tgf-β1 NM_021578 5’-GCTTCAGCTCCACAGAGAAGA-3’ 5’-CCAGGCTCCAAATGTAGGGG-3’ 
Cx43 NM_010288 5’-AGCTAGGCGGCAAAAGTAGG-3’ 5’-ACTCACTCATGTATACAGAACCAT-3’ 
Ck19 NM_008471 5’-GTCGAGGGAGGGGTTAGAGT-3’ 5’-CCATCTGAGCTACCAGCGAG-3’ 
Ggt1 NM_008116 5’-CAGCACCACAGGAAAAGTTGAG-3’ 5’-ACGGATTTCACCAGGGACAG-3’ 
Itgb4 NM_001005608 5’-GACCTATGAAGAAGGTGCTC-3’ 5’-GGCTCAGATGCGTGCCATAG-3’ 
Sox9 NM_011448 5’-AGTACCCGCATCTGCACAAC-3’ 5’-TACTTGTAATCGGGGTGGTCT-3’ 
EpCam NM_008532 5’-CTGGGAGGAGGATAAAGC-3’ 5’-AGAAGAATGGAACAGGGAC-3’ 
Hprt1 NM_013556 5’-CAAACTTTGCTTTCCCTGGT-3’ 5’-TCTGGCCTGTATCCAACACTTC-3’ 
Rantes NM_031116 5’-TGCCCACGTGAAGGAGTATTTTTA-3’ 5’-TGGCGGTTCCTTCGAGTGACAA-3’ 
Pdgfb NM_011057 5’-ATCCGCTCCTTTGATGATCT-3’ 5’-GAGCTTTCCAACTCGACTCC-3’ 
Mip1α NM_011337 5’-CTGCCCTTGCTGTTCTTCTC-3’ 5’-CTTGGACCCAGGTCTCTTTG-3’ 
Mcp-1 NM_011333 5’-GCTGACCCCAAGAAGGAATG-3’ 5’-GTGCTTGAGGTGGTTGTGGA-3’ 
hCcr1 NM_001295 5’-CCTGCTGACGATTGACAGGTA-3’ 5’-TTGGAAAAGTATAAGCCTGGCAT-3’ 
hCcr5 NM_000579 5’-TGCTACTCGGGAATCCTAAAAACT-3’ 5’-TTCTGAACTTCTCCCCGACAAA-3’ 
Hnf4α NM_008261 Qiagen QuantiTect cat.no. QT00144739 
Alb NM_009654 Qiagen QuantiTect cat.no. QT00115570 
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Supplementary Figure Legends 
Supplementary Figure 1. GGT enzyme activity in conditioned medium from PIL-2 cells 
treated ± 150 µM taurocholate (Figure 5D), normalized to protein concentration at the 
conclusion of the experiment (day 4). Data are expressed as mean ± SEM and statistical 
significance was assessed using Student's t-test where ***p<0.001.  
 
Supplementary Figure 2. Expression levels of Ccr1 and Ccr5. LX-2 cells were examined 
for Ccr1 and Ccr5 mRNA expression relative to the abundant housekeeping gene Hprt1. Data 
are expressed as mean ± SEM and statistical significance was assessed using Student's t-test 
where ****p<0.0001. 
 
